ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: LB15

Dietary Fiber Supplementation Enhances Methotrexate Response and Restores Th17/Treg Balance in Rheumatoid Arthritis: Results from the Superfibre Randomized Trial

Claire Immediato Daien1, Jean-Pierre Hellier2, Zübeyir Salis3, Gaël Mouterde4, Jacques Morel5, Laurence Macia6 and Rachel audo4, 1CHU and Univesrity of Montpellier, Montpellier, France, 2CHU Montpellier, Arles, France, 3University of Montpellier, Montpellier, France, 4CHU Montpellier, Montpellier, France, 5CHU and University of Montpellier, Montpellier, France, 6Sydney University, Brisbane, Australia

Meeting: ACR Convergence 2025

Date of first publication: October 13, 2025

Keywords: diet, Late-Breaking 2025, Measurement, microbiome, rheumatoid arthritis, TH17 Cells

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: (LB01–LB18) Late-Breaking Posters

Session Type: Poster Session

Session Time: 10:30AM-12:30PM

Background/Purpose: Gut dysbiosis and Th17/Treg imbalance contribute to rheumatoid arthritis (RA). Additionally, methotrexate (MTX) efficacy depends on gut microbiota composition, especially on the presence of B. fragilis and butyrate (Zhou B, et al. Front Microbiol. 2022). Dietary fibres improve gut microbiota composition and increase microbiota-derived short-chain fatty acids including butyrate, that may restore immune tolerance.We aimed to evaluate whether dietary fiber supplementation in patients with RA improves disease activity, Th17/Treg balance and response to MTX.

Methods: Superfibres was a randomized, double-blind, placebo-controlled trial, including  patients with active RA despite stable doses of csDMARDs. Patients were randomized 1:1 to inulin (12 g/day) or placebo for 30 days.  EULAR response and change in peripheral Th17/Treg subsets (flow cytometry) were compared. Subgroup analyses compared MTX vs. non-MTX patients.

Results: A total of 49 patients were included (26 in the fiber group, 23 in the placebo group) with 85.7% women, a mean age of 62 ± 10 years and a mean DAS28 was 3.86 ± 0.61. Odds of EULAR response were markedly higher with fiber (OR 4.65, 95% CI 1.15–18.9; p=0.03). Fiber reduced circulating Th17 cells and the Th17/Treg ratio compared with placebo (p < 0.02). A significant treatment × MTX interaction was observed (p=0.011). In MTX users, mean ΔDAS28 was –1.00 with fiber vs –0.34 with placebo (Fig. 1). No effect was seen in non-MTX patients (n=6). Intervention was well tolerated, with >90% compliance.

Conclusion: This first placebo-controlled RCT of dietary fiber in RA shows that supplementation significantly increases EULAR response rates and improves Th17/Treg balance. This may be explained by an  enhanced MTX efficacy These findings establish the gut–immune axis as a novel therapeutic target and identify dietary fiber as a safe, inexpensive adjunct to MTX in RA. If confirmed, our results have the potential to change clinical practice and improve MTX efficacy in daily practice.

Supporting image 1DeltaDAS28 by treatment and background therapy.


Disclosures: C. Immediato Daien: AbbVie/Abbott, 2, Amgen, 6, Bristol-Myers Squibb(BMS), 6, Eli Lilly, 5, 6, Janssen, 6, Merck/MSD, 6, Novartis, 6, Pfizer, 6, UCB, 6; J. Hellier: None; Z. Salis: Zuman International Pty Ltd, 8; G. Mouterde: AbbVie/Abbott, 6, Alphasigma, 6, Eli Lilly, 6, Novartis, 6, Roche Chugai, 6, UCB, 6; J. Morel: Medac, 1, Nordic pharma, 6; L. Macia: Sanofi, 3; R. audo: None.

To cite this abstract in AMA style:

Immediato Daien C, Hellier J, Salis Z, Mouterde G, Morel J, Macia L, audo R. Dietary Fiber Supplementation Enhances Methotrexate Response and Restores Th17/Treg Balance in Rheumatoid Arthritis: Results from the Superfibre Randomized Trial [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/dietary-fiber-supplementation-enhances-methotrexate-response-and-restores-th17-treg-balance-in-rheumatoid-arthritis-results-from-the-superfibre-randomized-trial/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/dietary-fiber-supplementation-enhances-methotrexate-response-and-restores-th17-treg-balance-in-rheumatoid-arthritis-results-from-the-superfibre-randomized-trial/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology